| Literature DB >> 33545064 |
E Elizabeth Patton1, Kristen L Mueller2, David J Adams3, Niroshana Anandasabapathy4, Andrew E Aplin5, Corine Bertolotto6, Marcus Bosenberg7, Craig J Ceol8, Christin E Burd9, Ping Chi10, Meenhard Herlyn11, Sheri L Holmen12, Florian A Karreth13, Charles K Kaufman14, Shaheen Khan15, Sebastian Kobold16, Eleonora Leucci17, Carmit Levy18, David B Lombard19, Amanda W Lund20, Kerrie L Marie21, Jean-Christophe Marine22, Richard Marais23, Martin McMahon24, Carla Daniela Robles-Espinoza25, Ze'ev A Ronai26, Yardena Samuels27, Maria S Soengas28, Jessie Villanueva29, Ashani T Weeraratna30, Richard M White31, Iwei Yeh32, Jiyue Zhu33, Leonard I Zon34, Marc S Hurlbert35, Glenn Merlino36.
Abstract
There is a lack of appropriate melanoma models that can be used to evaluate the efficacy of novel therapeutic modalities. Here, we discuss the current state of the art of melanoma models including genetically engineered mouse, patient-derived xenograft, zebrafish, and ex vivo and in vitro models. We also identify five major challenges that can be addressed using such models, including metastasis and tumor dormancy, drug resistance, the melanoma immune response, and the impact of aging and environmental exposures on melanoma progression and drug resistance. Additionally, we discuss the opportunity for building models for rare subtypes of melanomas, which represent an unmet critical need. Finally, we identify key recommendations for melanoma models that may improve accuracy of preclinical testing and predict efficacy in clinical trials, to help usher in the next generation of melanoma therapies.Entities:
Keywords: animal models; drug discovery; immunotherapy; melanoma; targeted therapy; therapeutics; tumor microenvironment
Mesh：
Year: 2021 PMID： 33545064 PMCID： PMC8378471 DOI： 10.1016/j.ccell.2021.01.011
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743